AlpInvest Partners B.V. Acquires 302,354 Shares of UiPath Inc. (NYSE:PATH)

AlpInvest Partners B.V. increased its position in shares of UiPath Inc. (NYSE:PATH - Free Report) by 147.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 507,841 shares of the healthcare company's stock after purchasing an additional 302,354 shares during the quarter. UiPath accounts for 2.9% of AlpInvest Partners B.V.'s investment portfolio, making the stock its 13th biggest holding. AlpInvest Partners B.V. owned approximately 0.09% of UiPath worth $12,615,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D increased its position in UiPath by 3.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 231,613 shares of the healthcare company's stock worth $5,753,000 after buying an additional 7,918 shares in the last quarter. GAMMA Investing LLC purchased a new position in UiPath during the fourth quarter worth $36,000. New York State Common Retirement Fund increased its position in UiPath by 19.0% during the fourth quarter. New York State Common Retirement Fund now owns 363,056 shares of the healthcare company's stock worth $9,018,000 after buying an additional 58,064 shares in the last quarter. California Public Employees Retirement System increased its position in UiPath by 13.9% during the fourth quarter. California Public Employees Retirement System now owns 641,825 shares of the healthcare company's stock worth $15,943,000 after buying an additional 78,459 shares in the last quarter. Finally, Sigma Planning Corp purchased a new position in UiPath during the fourth quarter worth $809,000. 62.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $22.84, for a total transaction of $365,440.00. Following the sale, the chief financial officer now directly owns 87,505 shares in the company, valued at approximately $1,998,614.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have sold 72,000 shares of company stock worth $1,591,360. 31.03% of the stock is currently owned by company insiders.

UiPath Price Performance

PATH traded down $0.60 on Friday, reaching $20.71. The company's stock had a trading volume of 5,603,184 shares, compared to its average volume of 6,426,221. The stock has a market cap of $11.78 billion, a price-to-earnings ratio of -121.82 and a beta of 0.96. UiPath Inc. has a 1 year low of $12.38 and a 1 year high of $27.87. The business's 50 day moving average is $23.30 and its 200 day moving average is $21.44.

UiPath (NYSE:PATH - Get Free Report) last announced its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The firm had revenue of $405.25 million for the quarter, compared to analysts' expectations of $383.32 million. As a group, research analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PATH shares. Evercore ISI lifted their price objective on UiPath from $24.00 to $27.00 and gave the company an "in-line" rating in a research report on Thursday, March 14th. KeyCorp started coverage on UiPath in a research report on Monday, April 8th. They issued an "overweight" rating and a $27.00 price objective for the company. Bank of America lifted their price objective on UiPath from $26.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 price objective on shares of UiPath in a research report on Wednesday, March 20th. Finally, Canaccord Genuity Group lifted their price objective on UiPath from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, March 15th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.